Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Oslo, 8 July 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 19 June 2024 regarding the general meeting's approval of a rights issue of between 3,658,000 new shares to 20,732,010 new shares in the Company, at a subscription price of NOK 2.50 per share (the "Offer Shares") (the "Rights Issue"). In addition, the subscribers in the Rights Issue will be allocated one warrant for every Offer Share allocated to them and paid by them in the Rights Issue (the "Warrants") without additional consideration.
The subscription period for the Rights Issue expired today, on 8 July 2024 at 16:30 hours (CEST).
The preliminary results indicate that the Company has received subscriptions for a number of Offer Shares which entail gross proceeds of approximately NOK 17.8 million from the Rights Issue. The remaining amount up to the secured minimum financing of NOK 19.395 million, will be covered through the subscription of additional convertible bonds as part of Atlas' commitment to the Rights Issue (the "CB Commitment").
Further, Atlas has undertaken to finance the Company's remaining financial needs until end of June 2025, up to a monthly cash requirement of NOK 4 million (the "Financing Commitment"), complementing the proceeds from the Rights Issue including proceeds from investors' exercise of the Warrants in December 2024. In addition, as a related transaction to the Rights Issue, Atlas shall settle NOK 15 million of the amount owed to Atlas under the Investment Agreement and Bond Terms by the issuance of new shares at the subscription price in the Rights Issue (the "Conversion").
The final allocation of the new shares will take place tomorrow, on 9 July 2024, in accordance with the allocation criteria set out in the Company's securities note approved on 18 June 2024 (the "Securities Note" and together with a registration document supplement and summary, approved on 18 June 2024, and a registration document approved on 28 September 2023 and a registration document supplement approved on 8 March 2024 comprises the "Prospectus"). The final result of the Rights Issue will be published shortly thereafter, and letters regarding allocation of new shares and the corresponding subscription amount to be paid by each subscriber, are expected to be distributed during the course of tomorrow, on 9 July 2024.
The payment date for the new shares is 10 July 2024.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Mats Hermansen, VP Finance at Circio Holding ASA, at the date and time as set out above.